Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 4 of 65 · 3077 articles
Patients and clinicians worry isotretinoin might trigger flares in people with existing IBD. This study suggests that among patients with stable, well-controlled Crohn's or UC, isotretinoin did not generally worsen...
Families and clinicians often wonder whether H. pylori infection in childhood affects risks for asthma, IBD, celiac disease, or other immune-mediated disorders.
This review compiles preclinical evidence that propolis (a natural bee product) reduced inflammation and improved gut barrier and microbiota in animal models of colitis, so it may be a candidate for future clinical...
This preclinical study suggests a food-derived peptide formulation might reduce inflammation and improve intestinal barrier markers in lab and mouse models of ulcerative colitis, which could interest people exploring new...
Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Research and clinical trials. The original article is from International journal of nanomedicine.
This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...
This study highlights a potential microbiome–bile acid–immune pathway that could be relevant to ulcerative colitis and suggests a traditional herbal formula may influence that pathway in mice. Patients interested in...
The study offers a validated tool to estimate risk of postoperative recurrence after ileocolonic resection and shows that postoperative biologic prophylaxis markedly lowers early endoscopic recurrence—information that...
Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Ulcerative colitis and Research and clinical trials. The original article is from Przegla̜d Gastroenterologiczny.
People with ulcerative colitis may be interested because the study suggests a combined probiotic approach could strengthen gut bacteria functions linked to a protective metabolite (spermidine) and reduce colitis-like...
A preclinical mouse study found that heat-inactivated Lacticaseibacillus paracasei PC-01 reduced colitis signs and altered gut microbiota, which may be of interest for microbiome-targeted IBD research but does not show...
A new dual-targeting combination (IL-23 + α4β7) showed higher endoscopic remission rates than either drug alone in a Phase IIa Crohn's study, suggesting a potential new approach for patients who need better mucosal...
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Positive Phase 3 pediatric data could expand access to Omvoh for children with ulcerative colitis and change treatment options. That matters to families, clinicians, and patients using or considering biologic therapy.
Early antibody signatures could allow earlier identification of people at higher risk for Crohn’s disease or ulcerative colitis, which might eventually enable closer monitoring or preventative research.
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...
Early Phase 2a data suggest a dual-target IBD therapy (ABBV-466) produced higher endoscopic remission than single-pathway agents, which could matter if later trials confirm better outcomes for people with...
This mid-stage trial suggests a dual-targeting combo may improve endoscopic remission rates in Crohn’s disease compared with IL-23 inhibition alone, which could influence future treatment options and company strategies...
This preclinical study identifies a parasite-derived fluid that reduced inflammation, oxidative stress, and microbiome disruption in a mouse model of ulcerative colitis and in intestinal cells, pointing to possible new...
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
Overlap of EoE and IBD appears uncommon but more frequent than in the general population and is linked to more allergic disease and higher steroid exposure without clearer increases in esophageal scarring. That may...
This study suggests coconut oil and its myristic acid component reduced Crohn’s-like inflammation in a mouse model via effects on the microbiome and regulatory T cells, which could point toward new dietary or adjunctive...
The study links lower vitamin D and higher TNF‑alpha with greater UC severity and with each other, suggesting these measurable biomarkers may reflect inflammation in ulcerative colitis.
This study tested a blood biomarker (zonulin) tied to gut barrier function and found no evidence of increased intestinal permeability in these Behçet syndrome patients, unlike in the Crohn’s disease group.
Patients with upper GI Crohn’s often have a more aggressive course; this registry analysis suggests they usually respond to biologic drugs similarly to other patients but still carry a higher long-term chance of needing...
If validated, antibody-based signals found years before symptoms could allow earlier risk identification and research into why immune responses precede IBD. That may matter for patients and clinicians interested in early...
Cure8 found this source from intellectia.ai, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
Cure8 could only read part of this source from endpoints.news, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
New Phase 2a data suggest a combination therapy (ABBV-466) produced higher endoscopic remission at Week 24 than either component alone — a potential sign that multi-target approaches might improve Crohn's outcomes.
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
PRO2 and PRO3 were recorded far more often than CDAI or HBI in routine care and correlated strongly with those clinician-scored indices, so they may be a practical way to monitor Crohn’s activity and support real-world...
Multi-omics and AI approaches could improve biomarker discovery and predictive models that matter for earlier diagnosis and personalised treatment strategies in IBD, but practical use is limited today by data and...
The study suggests a colon-targeted herbal treatment altered metabolic and immune pathways and reduced inflammation in a rat model of ulcerative colitis, which could point to new therapeutic approaches to explore for UC...
People with Crohn's disease may be interested because the paper provides molecular hypotheses linking acupuncture to immune-related pathways (neutrophils, M2 macrophages) and nominates FER as a potential...
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
This study uses transcriptomics, single‑cell data, and machine learning to nominate lactylation‑related genes as biomarkers and drug targets in ulcerative colitis, which could guide future biomarker or drug‑repurposing...
The study explores whether people with UC in deep histologic remission can reduce or stop maintenance medications without losing remission — a question many patients and clinicians face because of medication costs, side...
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
A combo that adds an α4β7 blocker to an IL-23 inhibitor showed higher endoscopic remission at Week 12 than either drug alone in a phase 2 Crohn’s trial, which could point to a new treatment strategy for people who’ve...
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
An experimental mouse study suggests gastrodin may reduce colitis severity and associated anxiety/depression-like behaviours while changing gut microbiota, metabolites, and intestinal inflammation — an early preclinical...
The report suggests a dual-targeting antibody combination (IL-23 p19 + α4β7) may achieve higher endoscopic remission than either mechanism alone in a treatment-experienced Crohn's population, which could matter for...
This review summarizes how ulcerative colitis trials have been designed recently and flags common weaknesses (small samples, short follow-up, overreliance on Mayo score). Better-designed trials could produce results that...
If validated, antibody signatures could enable earlier identification of people at higher risk of developing IBD and help predict which patients may develop more severe disease, creating opportunities for earlier...
If validated, antibody-based signatures could enable much earlier detection of IBD and help identify people at risk of more severe Crohn’s disease years before symptoms—potentially opening opportunities for research on...
If validated, blood antibody patterns could allow earlier identification of people at risk for Crohn’s disease or ulcerative colitis — potentially before bowel damage occurs — opening opportunities for earlier monitoring...
